Gamunex-C (Immune Globul G/Gly/IgA Avg 46) — Medicare Part D spending
Grifols Therape · Rank #109 by total Part D spend · CMS data year 2023
Medicare Part D spent $482,557,331 on Gamunex-C (Immune Globul G/Gly/IgA Avg 46) in 2023, the #109 drug by total Part D spending out of 3,598 drugs. That worked out to about $13.22 per dosage unit, $8,498 per claim and $106,690 per beneficiary, across 56,783 claims for 4,523 beneficiaries. Average spending per dosage unit rose +3.0% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Gamunex-C (Immune Globul G/Gly/IgA Avg 46) spending at a glance (2023)
| Metric | Gamunex-C (Immune Globul G/Gly/IgA Avg 46) |
|---|---|
| Total Part D spending (2023) | $482,557,331 |
| Total spending (2022) | $447,474,208 |
| Year-over-year change in total spending | +7.8% |
| Average spending per dosage unit (2023) | $13.22 |
| Change in spend per dosage unit (YoY) | +3.0% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +3.9% |
| Average spending per claim (2023) | $8,498 |
| Average spending per beneficiary (2023) | $106,690 |
| Total claims (2023) | 56,783 |
| Beneficiaries (2023) | 4,523 |
| Total dosage units (2023) | 36,287,223 |
| Manufacturer(s) | Grifols Therape |
| National rank by total spend (of 3,598 drugs) | #109 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $447,474,208 | $482,557,331 | +7.8% |
| Avg spend per dosage unit | $12.83 | $13.22 | +3.0% |
| Avg spend per claim | $8,782 | $8,498 | — |
| Avg spend per beneficiary | $103,967 | $106,690 | — |
| Total claims | 50,954 | 56,783 | — |
| Beneficiaries | 4,304 | 4,523 | — |
How Gamunex-C compares with nearby drugs
Drugs with total Part D spending closest to Gamunex-C (Immune Globul G/Gly/IgA Avg 46):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Gamunex-C (Immune Globul G/Gly/IgA Avg 46) (this drug, #109) | $482,557,331 | $13.22 | +3.0% |
| Losartan Potassium (#107) | $487,624,151 | $0.19 | +20.4% |
| Lynparza (Olaparib) (#108) | $487,431,793 | $136.01 | +6.9% |
| Nurtec ODT (Rimegepant Sulfate) (#110) | $478,240,312 | $125.61 | +4.5% |
| Praluent Pen (Alirocumab) (#111) | $475,918,669 | $258.62 | +5.5% |
| Taltz Autoinjector (Ixekizumab) (#112) | $474,538,369 | $6,885.05 | +5.9% |
Frequently asked questions
How much does Medicare Part D spend on Gamunex-C?
Medicare Part D spent $482,557,331 on Gamunex-C (Immune Globul G/Gly/IgA Avg 46) in 2023 (the latest CMS data year), across 56,783 claims for 4,523 beneficiaries. That ranks #109 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Gamunex-C?
In 2023, the weighted average Medicare Part D spending per dosage unit for Gamunex-C (Immune Globul G/Gly/IgA Avg 46) was $13.22. Compared with 2022 it rose +3.0%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Gamunex-C?
CMS attributes Gamunex-C (Immune Globul G/Gly/IgA Avg 46) to Grifols Therape in the 2023 Part D spending file. Average spending per claim was $8,498 and per beneficiary $106,690.
Is the Gamunex-C figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20